Incorporating concentration and transportation of solar light into buildings via optical fibers.
Comprised of an Optimized Static Collector (OSC), a light concentrator module, a light transporting optical fiber, and a light dispersing end unit.
Aferrix has developed a novel technology for early diagnosis and monitoring of toxic iron in the serum. The company has developed several methods that quantify different forms of toxic iron in the serum, which are not detected by conventional tests. One of them is the FeROS™ LPI assay for the detection of Labile Plasma Iron (LPI), which is the redox active and chelatable iron fraction of Non-Transferrin-Bound- Iron (NTBI). Currently, Aferrix offers iron testing services and laboratory kits for research and treatment centers that specialize in iron overload diseases (Thalassemia, Hemochromatosis, Myelodysplastic syndrome) and to pharmaceutical companies that are developing iron chelators
Tavor has created the KNEE-T-NOLTM, an artificial implant for ACL (Anterior Cruciate Ligament) reconstruction surgery, answering the need of 600,000 procedures which performed annually in this global market of $1.9B. The KNEE-T-NOLTM is a ligament prosthesis made from braided, super-elastic NiTinol strands. The braid is attached at the femoral and tibial ends using standard fixation devices such as cortical buttons, cross pins or screws. Until today, all attempts to produce synthetic ligaments for the ACL were based on polymeric materials, which failed within a few years of usage due to their mechanical features such as fatigue and creep. Tavor’s ligament is designed to bear the mechanical burden, without suffering from these ailments. A clinical trial was successfully begun on March 2011 by implanting the KNEE-T-NOLTM in a two human patient, as part of an on-going multi-center clinical study. Initial results indicate an excellent rehabilitation progress
Oxitone Medical is developing a unique absolute wristwatch-like wearable pulse oximeter for continuous pulse rate and blood oxygen saturation monitoring. The uniqueness of this device is in measuring the pulse rate and oxygen saturation without conventional fingertip sensors and wires. All sensors are placed at the wrist location and embedded into convenient and familiar wristwatch-like enclosure. Millions of people worldwide are using noninvasive blood oxygen saturation (SaO2) monitors to assess their health before, during or after the therapy. However, some diseases assessing, diagnostics and therapy require a blood oxygen saturation control in continuous manner, mostly at home environment. The problem of patients, physicians and healthcare providers is that the current spot-check and hand held pulse oximeters using inconvenient, irritating and permanently falling fingertip sensor are not applicable for continuous home, out-patient monitoring and preventive medicine without compromising patients’ sleep or daily activity. Portable pulse oximetry market is estimated as ~200M$ with ~9-11% compound annual growth. The key customers for the wrist pulse oximeter are 5000 sleep labs, 16100 nursing homes and ~30M sleep disorders, pulmonary diseases and congestive heart failure patients (EU, USA).
MinInvasive Ltd., founded in 2011, is a privately held MedTech company developing its OmniCuff platform – a cost-saving, single-patient use device enabling transosseous rotator cuff repair (RCR) which obviates the need for suture anchors. The OmniCuff Device is FDA Class I [510(k) exempt]. The Company recently completed a 30 patient, multi-center, clinical feasibility study in the USA and maintains a strong intellectual property portfolio. MinInvasive is supported by Access Medical Ventures, Anatomy Medical Technology Fund, ATI Technologies Ltd. and private investors based in Israel and the USA.
Magen, commenced on November 2011 within Gefen, develops the SpineShield, TendonShield and NerveShield to address the $1B worldwide orthopedic anti-adhesion market. Adhesions usually form in the first 30 days after orthopedic surgery. Adhesion‐related complications are common, result in complications such as severe pain and /or impaired function. Magen products offer a physical barrier and mechanical strength to separate and provide a space between scar and normal tissues (e.g. the SpineShield protects the dura and spinal cord from formation of unwanted postoperative scars, fibrosis and blood penetration following laminectomy). Succeeding healing, the barrier is untwined out of the body. The SpineShield acquired CE Mark and successfully demonstrated its activity in 3 patients.
G&G Biotechnology Ltd. is launching a complete product line of light weight breast implants, for augmentation and reconstruction, based on its patented B-lite™ technology. G&G’s implants have been designed and rigorously tested for both quality and safety, creating the world’s lightest breast implant. Breast augmentation is currently one of the world’s most common cosmetic surgical procedures, with an annual growth seen both in the number of augmentations performed, and the size of implants chosen. The heavier the implant, the greater the side effects caused as a result of it, including ptosis, sagging, deformity, breast tissue atrophy, traction rippling, prominence of implants through breast tissue, stretch marks, back, shoulder and neck pain. G&G’s product line enables women to choose the larger volume implants they desire, while reducing the risks associated with the increased weight.
Clear-Cut Medical develops an intra-operative compact, simple and affordable MRI system for detecting surgical margins in breast cancer surgery. MRI is a well-established medical imaging technology, specifically for imaging cancer. Unfortunately, the size and cost of conventional MRI make it impractical for intra-operative use. Clear-Cut’s MRI technology is designed to bring the detection power of MRI to the hands of the surgeon and enable the surgeon to get a real time, simple and clear indication whether the removed lump margins are positive or negative. In case positive margins are detected, the surgeon can excise within the same procedure an additional few millimeters of tissue as guided by Clear-Cut MRI system, and re-examine them, until all removed tissue has negative margins. All removed tissue is sent to pathology for final examination, as is done today. Such use of Clear-Cut MRI system in the procedure is aimed to significantly reduce the re-excision rates and its derived costs, time and patient inconvenience
ART Healthcare develops a novel solution for safe enteral nourishment. ART solutions include physiological monitoring and real-time prevention of aspiration pneumonia in enterally-fed patients. The company has already developed a working console and demonstrated system feasibility in a lab model and animal studies